 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635c4. The stock option was granted as an inducem 